Skip to main content
. 2017 Apr 24;112(3):32. doi: 10.1007/s00395-017-0619-0

Fig. 4.

Fig. 4

Ongoing large cardiovascular outcome trials in secondary prevention with PCSK9-inhibiting antibodies. The drugs are applied subcutaneously. The recruitment of ODYSSEY outcomes and FOURIER has been completed. The studies are event driven. LDL-C values are depicted in mg/dL (mM/L). CV cardiovascular, MI myocardial infarction, UA unstable angina